SG11202103509RA - Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof - Google Patents

Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof

Info

Publication number
SG11202103509RA
SG11202103509RA SG11202103509RA SG11202103509RA SG11202103509RA SG 11202103509R A SG11202103509R A SG 11202103509RA SG 11202103509R A SG11202103509R A SG 11202103509RA SG 11202103509R A SG11202103509R A SG 11202103509RA SG 11202103509R A SG11202103509R A SG 11202103509RA
Authority
SG
Singapore
Prior art keywords
aoah
genetically
stem cells
mesenchymal stem
cells overexpressing
Prior art date
Application number
SG11202103509RA
Inventor
Michael Callahan
Shirley H J Mei
Yan Wang
Maria Florian
Katelynn Rowe
Chyan-Jang Lee
Original Assignee
Ottawa Hospital Res Inst
United Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ottawa Hospital Res Inst, United Therapeutics Corp filed Critical Ottawa Hospital Res Inst
Publication of SG11202103509RA publication Critical patent/SG11202103509RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01077—Acyloxyacyl hydrolase (3.1.1.77)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
SG11202103509RA 2018-10-29 2019-10-29 Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof SG11202103509RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862752000P 2018-10-29 2018-10-29
PCT/CA2019/051526 WO2020087160A1 (en) 2018-10-29 2019-10-29 Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof

Publications (1)

Publication Number Publication Date
SG11202103509RA true SG11202103509RA (en) 2021-05-28

Family

ID=70462996

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202103509RA SG11202103509RA (en) 2018-10-29 2019-10-29 Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof

Country Status (11)

Country Link
US (1) US20220010281A1 (en)
EP (1) EP3874029B1 (en)
JP (1) JP7372982B2 (en)
KR (1) KR20210086662A (en)
CN (1) CN113166729A (en)
AU (1) AU2019370629A1 (en)
CA (1) CA3116196A1 (en)
ES (1) ES2962812T3 (en)
IL (1) IL282820A (en)
SG (1) SG11202103509RA (en)
WO (1) WO2020087160A1 (en)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929604A (en) * 1986-05-28 1990-05-29 Board Of Regents, The University Of Texas System Lipopolysaccharides of reduced toxicity and the production thereof
US5281520A (en) * 1990-09-12 1994-01-25 Zymogenetics, Inc. Method for producing acyloxyacyl hydrolase
CN101374964B (en) * 2005-12-09 2013-07-17 贝勒研究院 Module-level analysis of peripheral blood leukocyte transcriptional profiles
WO2010010551A2 (en) 2008-07-21 2010-01-28 Compugen Ltd. Novel angiopoietin derived peptides
GB0814249D0 (en) * 2008-08-04 2008-09-10 Cellerix Sa Uses of mesenchymal stem cells
BRPI1015179A2 (en) * 2009-06-19 2016-04-19 Merck Patent Gmbh Biomarkers and Methods for Determining Efficacy of Anti-Egfr Antibodies in Cancer Therapy
EP2626369A1 (en) 2011-11-24 2013-08-14 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Engineered mesenchymal stem cells and their therapeutic use
ES2742473T3 (en) * 2012-03-27 2020-02-14 Curevac Ag Artificial nucleic acid molecules for enhanced protein or peptide expression
SI3062811T1 (en) 2013-11-01 2020-07-31 Regeneron Pharmaceuticals, Inc. Angiopoietin-based interventions for treating cerebral malaria
JP6793902B2 (en) 2013-12-20 2020-12-02 ノバルティス アーゲー Adjustable chimeric antigen receptor
MX2017000142A (en) 2014-06-30 2017-07-28 Tigenix S A U Mesenchymal stromal cells for treating sepsis.
DK3242933T3 (en) * 2015-01-08 2019-06-03 Apceth Gmbh & Co Kg Genetically modified mesenchymal stem cell expressing alpha-1 antitrypsin (AAT)
US10639329B2 (en) 2015-06-12 2020-05-05 Lentigen Technology, Inc. Method to treat cancer with engineered T-cells
JP6992983B2 (en) 2015-09-15 2022-01-13 カンステム バイオテック カンパニー リミテッド A composition for the prevention or treatment of inflammatory diseases containing stem cells overexpressing SOD3 as an active ingredient.

Also Published As

Publication number Publication date
ES2962812T3 (en) 2024-03-21
AU2019370629A1 (en) 2021-05-20
WO2020087160A1 (en) 2020-05-07
EP3874029A1 (en) 2021-09-08
KR20210086662A (en) 2021-07-08
JP2022513379A (en) 2022-02-07
JP7372982B2 (en) 2023-11-01
EP3874029A4 (en) 2022-08-03
US20220010281A1 (en) 2022-01-13
EP3874029B1 (en) 2023-08-30
CN113166729A (en) 2021-07-23
CA3116196A1 (en) 2020-05-07
IL282820A (en) 2021-06-30

Similar Documents

Publication Publication Date Title
IL272541A (en) Purified mesenchymal stem cell exosomes and uses thereof
IL259586B (en) Genetically modified stem cells and uses thereof
EP3510145A4 (en) Immune cells derived from induced pluripotent stem cell
IL287553A (en) Modified pluripotent cells
HK1247959A1 (en) Method of distinguishing mesenchymal stem cells and method of determining purity of mesenchymal stem cells
IL263265A (en) Use of mesenchymal stem cells and parts thereof
IL277025A (en) Methods of enhancing stem cell differentiation into beta cells
EP3412775A4 (en) Mesenchymal stem cell expressing trail and cd, and use thereof
EP3591038A4 (en) Mesenchymal stem cells and pharmaceutical composition
SG11202107732XA (en) Dorsally-derived oligodendrocyte progenitor cells from human pluripotent stem cells
EP3299023A4 (en) Low-oxygen-treated mesenchymal stem cell and use thereof
IL275037A (en) Crispr-cas9 modified cd34plus human hematopoietic stem and progenitor cells and uses thereof
IL253063B (en) Genetically modified mesenchymal stem cells expressing alpha-1 antitrypsin (aat)
GB201701509D0 (en) Pluripotenet stem cells
EP3886880C0 (en) Processes and apparatuses for obtaining amniotic mesenchymal stem cells from amniotic fluid and cells derived thereof
EP3452500A4 (en) Mesenchymal stem cell proliferation
EP4034172A4 (en) Gene-engineered mesenchymal stem cells and applications thereof
EP3681288A4 (en) Adaptation of hollow-fiber-based cell culture technology for the manufacturing of neo-islets or exosomes from stem cells
EP3426268A4 (en) Pancreatic stem cells and uses thereof
EP3872164C0 (en) Isolating stem cells from adipose tissue
HK1254739A1 (en) Enrich and amplify highly potent human mesenchymal stem cells from elderly cell populations
EP3865571A4 (en) Synovium-derived mesenchymal stem cells and use thereof
SG11202108977YA (en) Non-viral modification of mesenchymal stem cells
EP3864140A4 (en) Analysis of viable and nonviable cells
IL282820A (en) Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof